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Abstract
The chemokine (C-C motif) receptor 5 (CCR5) that belongs to the family of G protein–coupled receptors is exploited by
macrophage tropic (R5) human immunodeficiency virus type 1 (HIV-1) to enter cells. Maraviroc, a small molecule CCR
antagonist, is used as a part of combination antiretroviral therapy to treat persons infected by R5 HIV-1. CCR5 is
expressed in various cancers, and its level of expression is a negative predictor of patients’ survival in gastric cancers.
Here, we report MKN45, MKN74, and KATOIII cells, three human gastric cancer cell lines with different stages of dif-
ferentiation, which express CCR5 as detected by flow cytometry and reverse transcription–polymerase chain reaction
(RT-PCR), and its ligand RANTES. In vitro experiments demonstrate that CCR5 antagonism reduces gastric cancer cell
migration induced by macrophage inflammatory protein 1α (MIP-1α), MIP-1β, and RANTES and adhesion to the ex-
planted murine peritoneum. Administration of maraviroc from days 3 to 10 after MKN45 cell inoculation to severe com-
bined immunodeficient (SCID) mice effectively reduced the extent of peritoneal disease and increased survival. Maraviroc
treatment also reduced the tumor burden in a xenograftmodel. Gene expression andRT-PCRanalyses revealed that CCR5
antagonism in vivo modulates the expression of genes known for their role in cancer growth including interleukin-10
receptor B; hepatocyte growth factor receptor (MET); the homolog of the atypical cadherin gene, FAT1; Nm23-H1;
and lymphotoxin β receptor. In summary, we have shown that CCR5 is mechanistically involved in dissemination of
gastric cancer cells, suggesting that small molecule inhibitors of CCR5 might be exploited for their anticancer potential.
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Introduction
Chemokines and their receptors are essential players in the immune
defense by directing and controlling the migration, activation, differ-
entiation, and survival of leukocytes. Chemokines exert their function
by binding and activating seven-transmembrane receptors belonging
to the superfamily of G protein-coupled receptors (GPCRs) [1].
Inappropriate or prolonged expression of chemokines and/or chemo-
kine receptors results in an excessive infiltration of leukocytes into
inflamed tissues, resulting in chronic inflammation, autoimmune
diseases, tumor growth, survival, and metastasis [1].
Gastric cancer is a leading cause of death for malignancies world-
wide. Despite diagnostic and therapeutic advances, the prognosis of
patients with advanced gastric carcinoma is poor and chemotherapy
holds risk for major toxicity [2]. Thus, understanding the molecular
mechanisms underlying gastric cancer growth and dissemination might
help in finding new specific and less toxic therapeutic approaches.
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Previous studies support a role for the chemokine (C-C motif) receptor
5 (CCR5) and one of its ligand CCL5 (RANTES) in gastric cancer
growth and dissemination [2]. This contention arises from the obser-
vation that tumor-infiltrating cells express CCL5, whereas tumor cells
express the CCL5 receptors and serum CCL5 levels correlate with
tumor progression and prognosis in patients with gastric and colorectal
cancers [2,3]. Further, stimulation with CCL5 promotes proliferation
of cancer cell lines [4].
In addition to its role in orchestrating leukocyte trafficking, CCR5 is
the major co-receptor molecule used by human immunodeficiency
virus type 1 (HIV-1) to enter cells. The CCR5Δ32 allele, which pro-
duces a prematurely truncated form of CCR5, is associated with pro-
found resistance to HIV-1 infection in homozygotes and a better
disease outcome in heterozygotes [5]. These observations have driven
the development of anti-HIV drugs that disrupt the virus-CCR5 in-
teraction, including the first-in-class–approved drug maraviroc [5].
Maraviroc is a noncompetitive, slowly reversible small-molecule antag-
onist of CCR5 that prevents signaling by all three ligands of CCR5 [i.e.,
CCL5/RANTES, macrophage inflammatory protein 1α (MIP-1α), and
MIP-1β] and is used as a part of combination antiretroviral therapy for
patients infected with CCR5-tropic HIV (i.e., a subtype that uses only
the CCR5 co-receptor to enter cells) [6–8].
Because maraviroc is clinically available [6] but its potential rele-
vance to gastric cancer therapy is unknown, we have designed a study
to investigate the effect of this agent in rodent models of gastric cancer
dissemination. Using maraviroc as a tool, we demonstrate that the
CCR5 pathway plays a mechanistic role on metastatic dissemination
of three gastric cancer cell lines and identified a novel therapeutic
target for this agent [7,8]. This study suggests that small molecule
inhibitors of CCR5 can be exploited for their anticancer potential.
Materials and Methods
Cell Lines
Three human gastric cancer cell lines THP1, KATOIII, and MCF7
were from American Type Culture Collection (ATCC, Promochem,
Milan, Italy), whereas MKN74 and MKN45 were from the Japanese
Collection of Research Bioresources (Human Science Research Re-
sources Bank, Osaka, Japan) [9–11]. Gastric cell lines were maintained
in RPMI medium with 10% FBS and penicillin/streptomycin at 37°C
in a humidified atmosphere of 5% CO2 in air. Cells were regularly
passaged to maintain exponential growth.
Animal Studies
Eight-week-old male nonobese diabetic–severe combined immuno-
deficient (NOD-SCID) mice (supplied by the animal center of the
University of Perugia, Perugia, Italy) were housed under pathogen-free
conditions. The care and use of the animals were approved by the
Institutional Animal Care and Use Committee of the University of
Perugia and were in accordance to European guidelines for care of
experimental animals. Protocols were approved by the Istituto Superiore
di Sanità (Rome, Italy), and the approval was granted to Prof Annibale
Donini (No. 208/2009/b). To generate models of experimental perito-
neal carcinomatosis and xenograft model, gastric cancer human cell lines
were injected intraperitoneally (i.p.) or subcutaneously, respectively, in
NOD-SCIDmice. To examine maraviroc anticancer potential in perito-
neal carcinomatosis, a single cell suspension of 1 × 107 MKN45 cells in
a total volume of 0.2 ml of medium without serum was injected into
the peritoneal cavity (i.p.) of each mouse using a 23-gauge needle, and
animals were randomized in control group 1 (n = 12) and group 2 (n =
12) treated with maraviroc (10 mg/kg, i.p.) for 7 days starting from day 3
after cell inoculation. The extent of peritoneal carcinogenesis was evalu-
ated on day 10 by necroscopy; both mesenteric and peritoneal nodules
were counted. In another set of experiments, the two groups of animals
mentioned above were observed until death, and overall survival was eval-
uated. To evaluate the role of anti-CCR5 molecule in tumor growth,
NOD-SCID mice were inoculated subcutaneously with MKN74 or
MKN45 (1 × 107 per mouse) cells. Mice were randomized into the fol-
lowing two groups (n = 8-10): control group and the other treated with
maraviroc per os at a dose of 50mg/kg twice a day. At sacrifice, all tissues
were immediately snap frozen in liquid nitrogen and stored at −80°C
until used or fixed in formalin.
CCR5 Expression
To assess CCR5 expression in MKN45, MKN74, and KATOIII
cell lines, cells were cultured at 37°C, in an atmosphere of 5% CO2,
in RPMI medium supplemented with 10% FBS, 1% L-glutamine,
and 1% penicillin/streptomycin in a six-well plate at 5 × 105 cells
per well. To evaluate CCR5 surface expression, cells were trypsinized,
transferred to a collection tube, and suspended in medium with 10%
FBS. After centrifugation at 1300 rpm for 10 minutes, cells were sus-
pended in 500 μl of phosphate-buffered saline (PBS), stained with 5 μl
of CCR5 antibody (Novus Biologicals, Cambridge, United Kingdom),
and incubated on ice for 30 minutes. Samples were washed with PBS,
centrifuged at 1300 rpm for 10 minutes, and stained with a fluo-
rescein isothiocyanate–conjugated goat anti-rabbit secondary antibody
(20 minutes at +4°C). Cells were washed twice with PBS and finally
suspended in 500 μl of PBS plus 1% formaldehyde; CCR5-positive
cells were assessed by flow cytometry. To evaluate CCR5 intracellular
expression, MKN45, MKN74, and KATOIII cells [10] were resus-
pended in 250 μl of Cytofix/Cytoperm solution (BD Biosciences),
incubated at +4°C for 25 minutes, and washed twice with 1× Perm/
Wash solution (BD Biosciences, Milan, Italy). After centrifugation at
1300 rpm for 10 minutes, 5 μl of CCR antibody (Novus Biologicals)
were added to each tube and cells were incubated on ice for 30 min-
utes. Samples were washed with 1× Perm/Wash solution, centrifuged
at 1300 rpm for 10minutes, and stainedwith a fluorescein isothiocyanate–
conjugated goat anti-rabbit secondary antibody (20 minutes at +4°C).
Cells were washed two times with 1× Perm/Wash solution and finally
suspended in 500 μl of PBS plus 0.04% formaldehyde and analyzed
by flow cytometry. Experiments were conducted in triplicate. MKN45
and MKN74 (3 × 107 per mouse) and KATOIII (1 × 107 per mouse)
cells were inoculated in the peritoneum of C57BL/6 mice (three ani-
mals per group); after 4 hours, mice were killed and peritoneal wash-
ings were collected to evaluate CCR5 surface expression on gastric
cancer cell lines. Retrieved cells were stained as described above, and
CCR5 expression was evaluated by flow cytometry using forward scatter
(FSC) and side scatter (SSC) discrimination gate to avoidmouse immune
cell contamination.
Proliferation Assay
MKN45, MKN74, and KATOIII cells (1 × 106) were plated onto
10-cm culture dish in RPMI medium supplemented with 10% FBS,
1% L-glutamine, and 1% penicillin/streptomycin. On day 2, cells were
left untreated or stimulated with 5 μM maraviroc for 72 hours. After
treatment, cells were trypsinized and resuspended in complete medium;
proliferation was assessed by trypan blue viability measurements. The
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values were expressed as percentage of proliferation inhibition compared
to nontreated cells. Experiments were conducted in triplicate.
Cell Adhesion to Peritoneum
Gastric cancer cell lines were plated onto complete RPMI me-
dium; on day 2, cells were starved and left untreated or pretreated with
5 μM maraviroc for 8 hours. Cells were subsequently triggered with
chemokines MIP-1α (20 ng/ml), MIP-1β (20 ng/ml), and RANTES
(10 ng/ml) for 36 hours [9]. On day 4, excised parietal peritoneum
(∼1.6 cm2) was placed in a 24-well culture plate, which had been filled
with 1.0 ml of 1% BSA/RPMI 1640. Gastric cancer cells were de-
tached, fluorescently labeled with BCECF-AM (3 μM) at 37°C for
30 minutes, and washed twice with 1% BSA/RPMI 1640. After
trypan blue staining, a suspension of living cells (5 × 105 cells/ml in
1% BSA/RPMI 1640; 0.5 ml) was overlaid on the peritoneum in a
24-well plate, and the plate was incubated at 37°C for 40 minutes.
After gentle washing with PBS, the cells adherent to the peritoneum
were lysed with 1.0 ml of 1% NP-40 and the fluorescence intensity
was measured with a fluorescence spectrophotometer (Ex = 490 nm
and Em = 520 nm). Experiments were conducted in triplicate.
Polymerase Chain Reaction Array Analysis
Total RNA was prepared from each specimen using TRIzol (Invitrogen,
Milan, Italy) to derive total RNA fromMKN45 xenograft nodules treated
with vehicle alone or maraviroc (nodules from three to four mice per
group were used). The RNA was reverse transcribed with SuperScript II
Figure 1. CCR5 is expressed by gastric cancer cell lines. (A and B) MKN45, MKN74, and KATOIII cells were evaluated by cytofluorometry
analysis. Data are means ± SE of six experiments. (C–E) Representative flow cytometry histograms of surface and intracellular CCR5
expression in MKN45, MKN74, and KATOIII cells. (F–H) CCR5 on MKN45, MKN74, and KATOIII implanted i.p. in mice. Data are means ±
SE of three experiments. (I and J) RT-PCR analysis confirmed the expression of CCR5 and RANTES on MKN35 and MKN74. Data are
means ± SE of four experiments.
Figure 2. CCR5 antagonism by maraviroc inhibits proliferation of gastric cancer cells. Exposure of MKN45, MKN74, and KATOIII cells to
maraviroc significantly inhibits cell proliferation. N = 4 to 6; *P < .05 versus control.
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Reverse Transcriptase (Invitrogen) following the manufacturer’s instruc-
tions. A total of 50 ng of cDNA was pipetted into each well of a 96-well
gene array plate [Human Tumor Metastasis RT2 Profiler PCR Array
(http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-028Z.
html) and Human Inflammatory Cytokines and Receptors RT2 Profiler
PCR Array (http://www.sabiosciences.com/rt_pcr_product/HTML/
PAHS-011Z.html), Superarray Biosciences, Frederick, MD] and ampli-
fied following the manufacturer’s instructions. These gene arrays are
designed to assess 84 genes known to be involved in metastasis and
inflammation, respectively. Genes selected for tumor metastasis array
encode several classes of protein factors including those for cell adhe-
sion, extracellular matrix components, cell cycle, cell growth and pro-
liferation, apoptosis, transcription factors and regulators, and other
genes related to tumor metastasis. Genes selected for inflammatory
cytokine and receptor array encode several classes of protein including
chemokines, chemokine receptors, interleukins, interleukin receptors,
other cytokines, and other cytokine receptors. Array analysis was carried
out with the online software RT2 Profiler PCR Array Data Analysis
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
The signal detected for each gene in the Human Inflammatory
Cytokines and Receptors Array was normalized to the signal obtained
for β-actin, β2-microglobulin, hypoxanthine phosphoribosyltransferase 1,
and large ribosomal protein P0 on the same gene array to derive gene
expression values for each gene. The signal detected for each gene in
the Human Tumor Metastasis Array was normalized to the signal
obtained for β-actin, β2-microglobulin, and large ribosomal protein
P0 on the same gene array to derive gene expression values for each
gene. Upregulated/downregulated genes are genes whose expressions
had been altered by more than 1.8.
Quantitative Real-Time Polymerase Chain Reaction
Quantization of nodule (from four to five mice per group) gene ex-
pression was performed by quantitative real-time reverse transcription–
polymerase chain reaction (RT-PCR). One microliter of RNA was
incubated with DNase I and reverse transcribed with SuperScript II
(Invitrogen) according to the manufacturer’s specifications. For real-
time PCR, 20 ng of template was used in a 20-μl reaction containing
a 0.2 μMconcentration of each primer and 10 μl of KAPA SYBR FAST
(Kapa Biosystems, Woburn, MA). The following PCR primers were
designed using the software Primer3 Output using published sequence
data obtained from the NCBI database.
hGAPDHs: gaaggtgaaggtcggagt;
hGAPDHas: catgggtggaatcatattggaa;
hIL10RBs: gggaacctgactttcacagc;
hIL10RBas: ccacaggacagaaggtgatg;
hLTBs: gaggaggagccagaaacaga;
hLTBas: agccgacgagacagtagagg;
hFAT1s: gacaatgcaccacaatttcg;
hFAT1as: gtgattacgccggacagttt;
hMETs: aagagggcattttggttgtg;
hMETas: ctcggtcagaaattgggaaa;
hNME1s: cattgcgatcaaaccagatg;
hNME1as: cggtccttcaggtcaacgta.
Figure 3. Promotion of gastric cancer cell adhesion to mouse peritoneum by CCR5 ligands is reversed by CCR5 antagonism. Treatment
of MKN45 (B), MKN74 (A), and KATOIII (C) with MIP-1α (20 ng/ml), MIP-1β (20 ng/ml), and CCL5/RANTES (10 ng/ml) increases the
adhesion of gastric tumor cells to mouse peritoneal tissue (∼1.6 cm2 placed in a 24-well culture plate). The adhesion was reversed
by pretreatment with maraviroc. N = 4 to 6 experiments; * P < .05 versus the CCR5 ligand alone.
Translational Oncology Vol. 6, No. 6, 2013 Maraviroc and Gastric Cancer Mencarelli et al. 787
Statistical Analysis
Data are expressed as means ± SE. Statistical significance was deter-
mined by one-way analysis of variance followed by the Tukey test. The
Mann-Whitney test was used to compare two groups of data. A value
of P < .05 was considered significant. GraphPad Prism version 3.0
was used for graphics and statistical analyses (GraphPad Software,
San Diego, CA).
Results
Expression and Function of CCR5 on Gastric Cancer
Cell Lines
By flow cytometry analysis, cell surface and intracellular expression of
CCR5 was detected in MKN45, MKN74, and KATOIII, three gastric
cancer cell lines (Figure 1, A–E ). We confirmed that the expression
of CCR5 on gastric cancer cells was relatively stable even after these
cells were implanted i.p. in mice (Figure 1, F–H ). The expression of
CCR5 and its ligand RANTES in gastric tumor cells was confirmed
by RT-PCR (Figure 1, I–J ). The expression of CCR5 in MKN45
and MKN74 cells was compared to that of Thp1 cells, a myelomono-
cytic leukemia cell line, and toMCF7 cells, a breast cancer cell line. The
RT-PCR analysis shown in Figure 1I demonstrates that the CCR5
expression was higher in Thp1 cells than inMKN45 andMKN74 cells.
Interestingly, the expression of CCR5 in MKN74 was close to that of
MCF7 cells. Further, detectable levels of RANTES were found in both
gastric cancer cell lines (Figure 1J ), thus indicating the potential for
an autoregulatory loop in gastric cancers.
To investigate whether CCR5 was functional, cells were cultured
in the presence of maraviroc, a small molecule CCR5 antagonist. As
shown in Figure 2, exposure to maraviroc effectively inhibited cell pro-
liferation (P < .05). Furthermore, pretreating MKN45, MKN74, and
KATOIII cells with maraviroc effectively inhibited the adhesion of these
cancer cell lines to murine parietal peritoneum. For these experiments,
gastric cancer cell lines were first preactivated by exposure to CCR5
ligands, i.e., MIP-1α (20 ng/ml), MIP-1β (20 ng/ml), and CCL5/
RANTES (10 ng/ml). As shown in Figure W1, MKN45 and MKN74
cells expressed detectable levels of RANTES. In Figure 3, A to C , all
three ligands effectively increased adhesiveness of gastric tumor cells to
mouse peritoneal tissue (∼1.6 cm2 placed in a 24-well culture plate;
n = 4-6 experiments; P < .05). Of relevance, these activities were reversed
by pretreating the cells withmaraviroc (n = 4-6 experiments;P < .05 versus
the CCR5 ligand alone).
CCR5 Antagonism Attenuates Gastric Cancer Cell
Dissemination In Vivo
As shown in Figure 4, A to C , treating mice with maraviroc (10 mg/
kg i.p.) for 7 days starting from day 3 after MKN45 (1 × 107 cells)
injection in mice significantly reduced the number of peritoneal and
mesenteric nodules, from 23.0 ± 2.8 to 7.2 ± 1.4 for peritoneal
nodules and from 13.7 ± 2. 4 to 2.4 ± 0.7 for mesenteric nodules
(P < .05), detected in the peritoneum at day 10 after cell inoculation.
Maraviroc also reduced the total volume of nodules (peritoneal and
mesenteric nodules), from 832.0 ± 59.0 to 336.0 ± 62.0 mm3 (P <
.05). Treatment with maraviroc had no effect on mouse body weight
Figure 4. In vivo effect of CC5 antagonism: maraviroc protects against gastric cancer cell implantation in the peritoneal cavity. (A–C) Treating
NOD-SCID mice with maraviroc (10 mg/kg i.p.) for 7 days starting from day 3 inhibits MKN45 (1 × 107 cells) implantation into the peritoneum
as measured by counting the number of peritoneal and mesenteric nodules at the time of autopsy. Maraviroc also reduces significantly the
total volume of nodules (peritoneal and mesenteric nodules), from 832 ± 59 to 336 ± 62 mm3. The extent of peritoneal carcinogenesis was
evaluated on day 10. (D) Treatment withmaraviroc had no effect onmice body weight. Data are from 10mice per group. (E) CCR5 antagonism
by maraviroc increases animal survival. In another experimental set, animals were observed until death, and overall survival was evaluated.
Maraviroc administration to mice implanted with MKN45 cells enhances the survival. Data are from 10 mice per group.
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(Figure 4D). Importantly, as shown in Figure 4E , treating NOD-
SCID mice implanted with MKN45 cells with maraviroc also
increased the animal survival. Thus, median survival time increased
from 30 to 46 days in mice administered maraviroc.
To evaluate the role of maraviroc in tumor growth in another
model, NOD-SCID mice were inoculated subcutaneously with
MKN74 or MKN45 (1 × 107/mouse) cells and followed for 30 days.
A group of animals was treated with maraviroc (50 mg/kg twice a
day) for 20 days starting on day 10. As illustrated in Figure 5, A
to E , treating mice with maraviroc resulted in a significant reduction
of tumor burden in both MKN45 (Figure 5, B and C ) and MKN74
(Figure 5, D and E ) transplanted mice. The histopathology analysis
of xenograft nodules demonstrates that with both cell types the ad-
ministration of maraviroc resulted in extensive intratumoral necrosis
(Figure 5, F–M ), which is consistent with our observation that mar-
aviroc reduces proliferation of MKN45 and MKN74 cells (Figure 2).
PCR Array Analysis of Cancer Nodules from
MKN45 Xenografts
Because maraviroc reduces the gastric cancer cell line proliferation
in vitro and subcutaneous nodule volumes in vivo, we have then
investigated the molecular mechanisms involved in these effects. For
these purposes, two gene arrays designed to analyze the expression
of genes related to tumor metastasis and inflammatory cytokines
(chemokines and their receptors) were used. RNA from MKN45
xenografts was used for these studies. For the tumor metastasis array,
the expression of 15 genes was undetected, the expression of 6 genes
[hepatocyte growth factor receptor (MET ), FAT1, MDM2, PNN,
CTSK, and APC] was downregulated by less than 1.8-fold, whereas
3 genes [NME1, vascular endothelial growth factor A, and PLAUR] were
upregulated ≥+1.8 (P ≤ .05) in response to maraviroc treatment in
vivo (Figure 6, A–C ). For the inflammatory cytokines/chemokines
and receptors, the expression of 39 genes was undetected, the expres-
sion of 8 genes [NAMPT, interleukin-10 receptor B (IL-10RB), IL-16,
IL-1RN, lymphotoxin β receptor (LTB), IL-15, IL-5RA, and IL-17c] was
downregulated ≤−1.8, whereas only 1 gene (IL-27) was upregulated
≥+1.8 (P ≤ .05) in response to maraviroc treatment in vivo (Figure 7,
A–C ). As shown in Figure 8, the modulatory effect of maraviroc
on IL-10RB, MET, FAT1, NME1, and LTB was confirmed with
RT-PCR (n = 4/5; P < .05 versus control group).
Discussion
The results shown in this report demonstrate that CCR5 is expressed
on gastric cancer cell lines and that its activation by the CCR5 ligands
Figure 5. CCR5 antagonism by maraviroc reduces tumor burden in the xenograft model. (A–E) MKN74 or MKN45 (1 × 107/mouse) cells
were implanted subcutaneously, and mice were treated with maraviroc (50 mg/kg twice a day) for 30 days. Data are from 8 to 10 mice
per group. (F–M) Histopathology analysis of xenograft nodules obtained at day 30. Treating animals with maraviroc (H, I and L, M in
comparison with vehicle treatment F, G and J, K) increased significantly the extent of tumor necrosis. Original magnifications, ×2 and
×10 (as indicated). Each image shown is representative of one nodule.
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MIP-1α, MIP-1β, and RANTES triggers an adhesion of these cells to
the peritoneum. In addition, we have provided compelling evidence
that maraviroc, a drug approved for the treatment of R5, CCR5-
trophic, HIV-1 reduces the proliferation of gastric cancer cell lines
in vitro and attenuates the cancer burden in vivo.
Previous studies have shown that RANTES and CCR5 are highly
expressed in gastric cancers [8] with lymph node metastasis and that
the expression level of RANTES in the lymph nodes with cancer
invasion was substantially increased, suggesting that RANTES and
its receptor CCR5 were associated with the metastatic potential of
this tumor [9,11]. Further, it has been reported that protein extracts
from lymph nodes harboring metastasis from gastric cancers yield
significant chemotaxis toward either primary gastric cancer cells
or AGS cells [9]. Importantly, these effects could be reversed by
RANTES antagonism, which indicates that RANTES and its recep-
tor participate in the migration of gastric cancer cells from primary to
metastatic sites [9].
Given the aggressive clinical behavior of gastric cancer and the
lack of targeted therapies, we have investigated the effects of CCR5
antagonism in regulating the invasiveness and metastatic potential of
MKN45, MKN75, and KATOIII cells, three human gastric cancer cell
lines [10]. These cell lines reflect clinicopathologic features of gastric
cancer subtypes in that they show different phenotypes and stages of
differentiation [10]. The results of in vitro studies demonstrate that
all three cell lines express CCR5 as evaluated by flow cytometry analy-
sis. Further, CCR5 antagonism effectively counteracts the proinva-
sive potential of these cells, attenuating the proliferation potential
and migration and adhesion to explanted murine peritoneum. Taken
together, these data support a previously unrecognized role for CCR5
antagonism in regulating gastric cancer cell proliferation and tendency
toward diffusion.
Because previous studies have shown that CCR5-deficient mice
develop less lung metastases than their wild-type counterparts [12]
and had a reduction in intratumoral accumulation of macrophages,
granulocytes, and fibroblasts, resulting in less angiogenesis [12], we
have examined whether CCR5 antagonism modulate the tendency
toward gastric cancer diffusion in vivo.
In vivo results demonstrate that treating SCID mice with maraviroc
reduces the peritoneal colonization by gastric cancer cells. This result
is consistent with previous studies in which inhibition of CCR5 ex-
pression or administration of anti-CCL5/RANTES neutralizing anti-
body to tumor-bearing mice reduced metastatic capability induced by
coinjection of breast cancer cells and mesenchymal stem cells [11,12].
Because preventing the homing of cancer cells to metastatic sites
is a desirable characteristic in an anticancer agent, we have further
investigated whether treatment with maraviroc prevented gastric can-
cer growth in a xenograft model. Again, results from these experiments
demonstrate that CCR5 blockage for 30 days effectively reduced the
burden of cancer nodules in mice implanted with MKN45 and
MKN74 cells by approximately 40%. These effects on tumor volume
Figure 6. CCR5 antagonism modulates the expression of inflammatory genes. MKN45 xenografts treated with vehicle alone or maraviroc
were used for these studies. While expression of 15 genes was undetected, the expression of 6 genes (MET, FAT1,MDM2, PNN, CTSK, and
APC) was downregulated by less than 1.8-fold (P< .05). The expression of 3 genes (NME1, vascular endothelial growth factor A, and PLAUR)
was upregulated by more than 1.8-fold (P < .05) in response to maraviroc treatment in vivo (A–C).
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Figure 7. CCR5 antagonism modulates the expression of inflammatory genes as assessed by tumor metastasis array. MKN45 xenografts
treated with vehicle alone or maraviroc were used for these studies. The expression of 39 genes was undetected, the expression of 8 genes
(NAMPT, IL-10RB, IL-16, IL-1RN, LTB, IL-15, IL-5RA, and IL-17c) was downregulated by a fold change ≤−1.8, whereas 1 gene (IL-27) was
upregulated by ≥+1.8 fold (*P ≤ .05) in response to maraviroc treatment in vivo (A–C).
Figure 8. Validation of gene array by RT-PCR. RT-PCR validation of gene array confirmed that maraviroc regulates the expression of IL-10RB,
MET, FAT1, NME1, and LTB. N = 4/5 per group. *P < .05.
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associated with a significant increase in intratumoral necrosis. This
histopathology pattern associates regulation of the expression of several
genes including IL-10RB, MET, FAT1, NME1, and LTB. The regu-
latory effects of maraviroc on these genes were confirmed by RT-PCR
analysis. IL-10RB is upregulated in several cancer types and its activa-
tion has been linked to the development of immune tolerance. IL-10 is
expressed in gastric cancer metastases, and a positive correlation exists
between serum IL-10 levels and progression of cancers [13]. Previous
studies have shown that expression of cytokines with a Th1 signature
(IL-2 and IFN-γ) is reduced in gastric cancers with lymph node metas-
tasis as compared with cancers without metastasis. In contrast, the
expression of IL-10 is markedly increased in gastric cancers with lymph
node metastasis [13]. This unbalance between Th1/Th2 cytokines has
been mechanistically linked to the high level of expression of RANTES
and CCR5 in gastric cancers with lymph node metastasis, suggesting
that RANTES/CCR5 axis might impair the regional immunity in
these cancers [9]. In the present study, we have confirmed this concept
by demonstrating that CCR5 antagonism counteracts the growth of
gastric cancer implants in the xenograft model and that this effect
associates with a robust down-regulation of IL-10RB. Thus, the pres-
ent results are a further confirmation that inhibition of IL-10/IL-
10RB pathway is helpful to enhance the antitumor immune response
and support a role for CCR5 in regulating immune response in the
tumor environment.
MET, also known as hepatocyte growth factor receptor, is a receptor
tyrosine kinase with an important role both in normal cellular func-
tion and in oncogenesis. In many cancer types, abnormal activation
of MET is related to poor prognosis and various strategies to inhibit
its function, including small molecule inhibitors, are currently in pre-
clinical and clinical evaluations. MET is a gene involved in regulating
autophagy [14,15]. Autophagy, a self-digesting recycling mechanism
with cytoprotective functions, is induced by cellular stress [15]. This
process is also induced on cytotoxic drug treatment of cancer cells
and partially allows these cells to escape cell death. Thus, because
autophagy protects different tumor cells from chemotherapy-induced
cell death, current clinical trials aim at combining autophagy inhibitors
with different cancer treatments. Previous studies have shown that in
gastric adenocarcinoma cell lines GTL-16 and MKN45, where MET
activity is deregulated because of receptor overexpression, MET inhibi-
tion leads to cell death paralleled by the induction of autophagy. A
combined treatment of MET inhibitors together with the autophagy
inhibitor or genetically impairing autophagy by knocking down the
key autophagy gene, ATG7, is reported to decrease viability of gastric
cancer cells [14]. It has been reported that in gastric cancer cells induc-
tion of cytoprotective autophagy in MET-expressing cells on MET
inhibition and a combination of MET and autophagy inhibition result
in significantly decreased cell viability [14]. Thus, despite the fact that
we have not defined the mechanism by which maraviroc abrogates
MET expression, regulation of this receptor tyrosine kinase might
support the antitumor activity of the CCR5 antagonist.
Another gene that was negatively regulated by maraviroc in the
xenograft model is FAT1, one of the four homologs of the atypical
cadherin gene FAT [16]. FAT1 plays a controversial role in cancer
growth and functions as a tumor-suppressive or oncogenic gene in
a context-dependent manner [16]. Thus, while from one side FAT1
loss has tumor-suppressive effect because it leads to activation of the
Wnt signaling pathway and to a reduced cell-cell adhesion, it is known
that FAT1 binds to ENABLE/vasodilator-stimulated phosphoprotein
protein promoting actin polymerization and cell motility, thus pro-
moting cell migration and invasion [16]. Importantly, its inhibition
might help in reducing neoplastic cell attachment and motility at the
metastatic sites.
The Nm23-H1 (NME1) gene is a metastatic suppressor identified
in a melanoma cell line and expressed in different tumors where its
levels of expression associate with reduced or increased metastatic
potential [17]. Nm23 is one of the more than 20 metastasis sup-
pressor genes confirmed in vivo. It is highly conserved from yeast to
human, implying a critical developmental function. Tumors with altera-
tion of the p53 gene and reduced expression of the Nm23 gene are
more prone to metastasis [17]. Reductions in Nm23 expression have
been associated with aggressive behavior in various tumors including
gastric carcinomas [18]. Importantly, its expression is inversely propor-
tional to themetastatic potential of these carcinomas.Despite high levels
of Nm23 gene expression observed in other tumors (i.e., thyroid car-
cinoma), in gastric cancer, reinduction of NME1 expression might
have a potential favorable effect on dissemination [17].
Activation of LTB initiates inflammation-induced carcinogenesis
and orchestrates primary tumorigenesis [19]. LTB expression/function
has been linked to tumor relapse in various cancer models through dis-
tinct mechanisms. Inhibition of LTB is of pharmacological relevance
in regulating inflammation [20] and cancer progression [21].
In clinical settings, maraviroc is administered at doses ranging from
150 to 600 mg twice a day. In humans, oral doses of 300 mg produce
an average Cmax of 1200 nM [6]. Because in mice 16 mg/kg produce
an average Cmax of 1045 nM [5], the doses of 10 and 50 mg/kg per
day administered during our experiments were clinically relevant and
indicate that the in vivo effects of maraviroc in immunodeficient mice
injected with gastric cancer cell lines manifest at clinically relevant doses
of the drug.
In summary, we have shown that CCR5 is expressed in gastric
cancer cells and that its antagonism by maraviroc, a noncompetitive,
slowly reversible small molecule that is used as a part of combination
antiretroviral therapy for patients infected with R5, CCR5-tropic,
HIV-1, inhibits gastric cancer cell proliferation and mobility in vitro
and effectively attenuates the tendency toward dissemination in vivo.
While these studies support a path toward the clinical use of CCR5
antagonists as novel treatments for advanced gastric cancer and mara-
viroc is clinically used in the treatment of CCR5-tropic HIV with a
very limited burden of side effects [6], properly designed clinical
studies are required to evaluate whether the present observations
extend to clinical settings.
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